reported that TP53 mutation accounted for 30% of mutated genes in patients with DLBCL, and 87.5% of TP53 mutation occurred in exons 5–8 encoding the DNA‐binding domain (DBD) region. Here, TP53 is linked to diffuse large B-cell lymphoma.